Compare AXR & RANI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | AXR | RANI |
|---|---|---|
| Founded | 1961 | 2012 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Homebuilding | Medicinal Chemicals and Botanical Products |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 131.8M | 126.8M |
| IPO Year | 2010 | 2021 |
| Metric | AXR | RANI |
|---|---|---|
| Price | $25.07 | $1.09 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 1 | 4 |
| Target Price | ★ $30.00 | $7.50 |
| AVG Volume (30 Days) | 6.9K | ★ 752.9K |
| Earning Date | 03-12-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 89.60 | 57.14 |
| EPS | ★ 1.68 | N/A |
| Revenue | ★ $12,831,000.00 | $1,633,000.00 |
| Revenue This Year | $10.12 | $274.77 |
| Revenue Next Year | N/A | $79.44 |
| P/E Ratio | $14.64 | ★ N/A |
| Revenue Growth | N/A | ★ 58.85 |
| 52 Week Low | $17.61 | $0.39 |
| 52 Week High | $29.00 | $3.87 |
| Indicator | AXR | RANI |
|---|---|---|
| Relative Strength Index (RSI) | 38.49 | 59.26 |
| Support Level | $24.12 | $1.07 |
| Resistance Level | $28.81 | $1.22 |
| Average True Range (ATR) | 0.73 | 0.07 |
| MACD | -0.36 | 0.03 |
| Stochastic Oscillator | 16.29 | 82.25 |
Amrep Corp through its subsidiaries is engaged in the Real estate business. Its activities include land sales and lease activities, which involve obtaining approvals and selling both developed and undeveloped lots to homebuilders, commercial users, and others, as well as investments in commercial and investment properties. The Company accounts for land sales, home sales, and other revenues. Its operating segments include Land development and Homebuilding. The firm generates a majority of its revenue from the Land development segment. Geographically, all the activities are carried out throughout the United States.
Rani Therapeutics Holdings Inc is a clinical-stage biotherapeutics company advancing technologies to enable the development of orally administered biologics to provide patients, physicians, and healthcare systems with a convenient alternative to painful injections. The company has developed the RaniPill capsule, which is designed to deliver a wide variety of drug substances, including antibodies, proteins, peptides, and oligonucleotides. RaniPill is a proprietary and patented platform technology, intended to replace subcutaneous or IV injection of biologics with oral dosing. The company is also engaged in developing RaniPill HC, which is intended to enable the delivery of drug payloads in liquid form with high bioavailability.